Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Clovis Oncology stock | $4.34

Learn how to easily invest in Clovis Oncology stock.

Clovis Oncology Inc is a biotechnology business based in the US. Clovis Oncology shares (CLVS) are listed on the NASDAQ and all prices are listed in US Dollars. Clovis Oncology employs 429 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Clovis Oncology

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Clovis Oncology stock price (NASDAQ: CLVS)

Use our graph to track the performance of CLVS stocks over time.

Clovis Oncology shares at a glance

Information last updated 2021-10-16.
Latest market close$4.34
52-week range$4.06 - $11.10
50-day moving average $4.53
200-day moving average $5.28
Wall St. target price$5.70
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.12

Buy Clovis Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Clovis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Clovis Oncology price performance over time

Historical closes compared with the close of $4.34 from 2021-10-15

1 week (2021-10-11) 0.70%
1 month (2021-09-16) -5.86%
3 months (2021-07-16) -14.06%
6 months (2021-04-16) -27.42%
1 year (2020-10-16) -27.61%
2 years (2019-10-18) 29.94%
3 years (2018-10-18) 29.96
5 years (2016-10-18) 32.93

Is Clovis Oncology under- or over-valued?

Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clovis Oncology's PEG ratio

Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Clovis Oncology financials

Revenue TTM $156.9 million
Gross profit TTM $128.4 million
Return on assets TTM -26.13%
Return on equity TTM 0%
Profit margin -197.75%
Book value $-0.56
Market capitalisation $513.9 million

TTM: trailing 12 months

Shorting Clovis Oncology shares

There are currently 26.6 million Clovis Oncology shares held short by investors – that's known as Clovis Oncology's "short interest". This figure is 6.3% up from 25.0 million last month.

There are a few different ways that this level of interest in shorting Clovis Oncology shares can be evaluated.

Clovis Oncology's "short interest ratio" (SIR)

Clovis Oncology's "short interest ratio" (SIR) is the quantity of Clovis Oncology shares currently shorted divided by the average quantity of Clovis Oncology shares traded daily (recently around 3.3 million). Clovis Oncology's SIR currently stands at 8.06. In other words for every 100,000 Clovis Oncology shares traded daily on the market, roughly 8060 shares are currently held short.

However Clovis Oncology's short interest can also be evaluated against the total number of Clovis Oncology shares, or, against the total number of tradable Clovis Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Clovis Oncology's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Clovis Oncology shares in existence, roughly 220 shares are currently held short) or 0.2285% of the tradable shares (for every 100,000 tradable Clovis Oncology shares, roughly 229 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Clovis Oncology.

Find out more about how you can short Clovis Oncology stock.

Clovis Oncology share dividends

We're not expecting Clovis Oncology to pay a dividend over the next 12 months.

Clovis Oncology share price volatility

Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $4.06 up to $11.1. A popular way to gauge a stock's volatility is its "beta".

CLVS.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 1.7624. This would suggest that Clovis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Clovis Oncology overview

Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc.

Frequently asked questions

What percentage of Clovis Oncology is owned by insiders or institutions?
Currently 1.642% of Clovis Oncology shares are held by insiders and 49.891% by institutions.
How many people work for Clovis Oncology?
Latest data suggests 429 work at Clovis Oncology.
When does the fiscal year end for Clovis Oncology?
Clovis Oncology's fiscal year ends in December.
Where is Clovis Oncology based?
Clovis Oncology's address is: 5500 Flatiron Parkway, Boulder, CO, United States, 80301
What is Clovis Oncology's ISIN number?
Clovis Oncology's international securities identification number is: US1894641000
What is Clovis Oncology's CUSIP number?
Clovis Oncology's Committee on Uniform Securities Identification Procedures number is: 189464100

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site